Laboratory analysis of the antibody-based Covid-19 therapy GlaxoSmithKline (GSK) is developing with US partner Vir has indicated the drug is effective against the new Omicron variant, the British drugmaker said on Thursday.<br /><br />WATCH MORE: https://thestartv.com/c/news<br />SUBSCRIBE: https://cutt.ly/TheStar<br />LIKE: https://fb.com/TheStarOnline
